We're looking not to decrease what we have. The truth is, it would make life easier if we did have fewer, but that wouldn't, I think, be in the public good. I think we're saying that we think that the amount, the severity and the depth of an audit on an outsider should be the same as it is on an insider in Canada.
This valsartan case is a particular one. There was nobody producing valsartan in Canada at the time. The market had been consolidated to two players, and they made some changes that were overlooked by the Chinese health authorities and by a lot of other people who visited them. It could happen again, but if somebody were to make valsartan in Canada, you would say they should have their process controlled the same way and audited the same way, and they should look at all the other parameters that could cause this type of defect in the product.